ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 229

Uric Acid and Incident Dementia over 10 Years

Pascal Richette1, Aicha Soumare2, Stéphanie Debette2, Thomas Bardin3,4 and Christophe Tzourio2, 1Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, 2INSERM Research Center for Epidemiology and Biostatistics (U897) Team Neuroepidemiology, Bordeaux, France, 3Service de Rhumatologie, Hôpital Lariboisière, Paris, France, 4Rhumatology Departement, Hôpital Lariboisière, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In patients with gout, maintaining the serum uric acid (SUA) levels too low with ULT is a matter of concern because UA is thought to be neuroprotective. However, the relation between UA and both dementia and cognitive function, in which both vascular mechanisms and oxidative stress are thought to play a role, has been poorly explored.

Methods: We assessed the longitudinal association between SUA levels and the risk of incident dementia (DSM-IV criteria) over 10 years of follow-up in a large cohort of elderly individuals (3C cohort). Additionally, we investigated the relation between SUA levels and change in cognitive function (minimental state examination, Benton and Isaac tests, Trail making tests) and change in brain MRI patterns (total brain volume, white matter lesions volume and infarct-like brain lesions). 

Results: The study sample comprised 1,769 individuals (mean age 72.4, male 39.6 %). During the 10,608 person-years of follow-up (median duration: 9.6 years), 134 participants developed dementia (crude incidence rate: 9.2/1000 person-years) with 94 (70.1%) classified as Alzheimer’s disease and 9 (6.7%) as vascular dementia. Dementia was associated with older age, depressive symptoms, and APOE-ε4 genotype. Increasing age and BMI, current smoking, renal impairment, hypertension, history of cardiovascular disease, low HDL cholesterol, hypertriglyceridemia, high CRP and IL-6 levels, as well as the use diuretics, or aspirin were associated with hyperuricemia (all P values <0.001). The multivariate HR of dementia among individuals in the highest tertile of SUA levels as compared with those in the lowest tertile was 1.67 (95% CI 1.04 to 2.71); P for trend=0.05). The association was stronger for vascular dementia (HR 6.37 (95% 0.61 to 66.98)) than for Alzheimer’s disease HR 1.71 (95% 0.97-3.03). There was no clear association between SUA levels and change in cognitive performance, nor with change in white matter lesions volume or brain structure as assessed with MRI.

Conclusion: These findings suggest that higher SUA levels are associated with an increase risk of dementia, mainly from vascular cause.


Disclosure: P. Richette, None; A. Soumare, None; S. Debette, None; T. Bardin, Novartis , Gilead Sciences , ViiV Healthcare , Bristol Myers-Squibb, Merck, Romark, Abbvie, 2,Gilead Sciences, ViiV Healthcare, tol Myers-Squibb, Merck, Eli Lilly, 5,Eli Lilly, 8; C. Tzourio, None.

To cite this abstract in AMA style:

Richette P, Soumare A, Debette S, Bardin T, Tzourio C. Uric Acid and Incident Dementia over 10 Years [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/uric-acid-and-incident-dementia-over-10-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uric-acid-and-incident-dementia-over-10-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology